Financial Report Preview | Facing the Test of Exceeding Expectations for Eight Consecutive Quarters - Pfizer Inc. (PFE.US) Q3 to Reveal the Investment Effectiveness of TrumpRx

Pfizer Inc. (PFE.US) will announce its third-quarter financial report before the US stock market opens on November 4 (Tuesday). The market expects its earnings per share to reach $0.64, a decrease of 39.6% compared to the same period last year; revenue is expected to be $16.52 billion, a decrease of 6.7% year-on-year. It is worth noting that this pharmaceutical giant has exceeded earnings expectations for eight consecutive quarters, but revenue has only exceeded market expectations in 63% of quarters. Recently, analysts' expectations for Pfizer Inc. have become cautious- in the past three months, earnings per share expectations have been revised down 15 times, and revenue expectations have been revised down 10 times. This adjustment reflects the market's concerns about Pfizer Inc.'s normalization of demand in the post-pandemic era. Since the beginning of the year, Pfizer Inc.'s stock price has fallen by over 7%, significantly underperforming the market's 16% increase. However, AudioCodes Ltd., the head of Beyond the Wall Investing, pointed out that based on recent company positives and the Trump administration's policy of temporarily postponing drug import tariffs for three years, Pfizer Inc.'s stock price is expected to rebound. Specifically, in late September, Pfizer Inc. promised to offer four prescription drugs (including the arthritis drug tofacitinib) with discounts of up to 85% through the "most favored nation treatment" pricing platform TrumpRx introduced by Trump, and pledged to invest $70 billion in drug production and research in the United States in exchange for a three-year tariff exemption. The upcoming financial report is also expected to reveal Pfizer Inc.'s progress in the field of cancer treatment and the substantial impact of tariff policies on profitability. In addition, the progress of the highly anticipated Metsera (MTSR.US) acquisition will also be a focal point- previously, Novo Nordisk A/S Sponsored ADR Class B increased its bid to $9 billion (equivalent to $77.75 per share), surpassing Pfizer Inc.'s $4.9 billion offer.